Less than 10% of people eligible to benefit from obesity jabs such as Wegovy have access to them, warns the global health agency as it releases its first recommendations on the therapies.
With over a billion individuals worldwide currently obese, it is urging increased and just availability to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our new guidelines affirms that obesity is a chronic disease that can be treated with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are key obstacles to broad availability to the injections that can aid individuals in losing substantial body mass, notes the organization.
GLP-1 Therapy Scarcity
Despite the present best projected scenario, the production of such drugs would only suffice for around 100 million people – less than 10% of the global need, per the health organization.
The advice encourages governments and firms to increase access, by strategies including patent sharing.
Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Injections Operate
The injections replicate a body's own hormone to delay gastric emptying, curb appetite and enhance satiety so users reduce food intake.
Patients typically see weight reduction in the initial weeks of commencing the regular doses.
Evidence points to users may regain a significant portion after a year of halting the treatment, when their normal hunger return.
Being above a healthy weight raises your chance for contracting medical conditions, such as diabetes, heart disease, stroke, and specific cancers.
Excess weight concerns individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
